These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 34757962)
1. Selective Microvascular Tissue Transfection Using Minicircle DNA for Systemic Delivery of Human Coagulation Factor IX in a Rat Model Using a Therapeutic Flap. Than PA; Davis CR; Rennert RC; Morrison SD; Findlay MW; Kay MA; Gurtner GC Plast Reconstr Surg; 2022 Jan; 149(1):117-129. PubMed ID: 34757962 [TBL] [Abstract][Full Text] [Related]
2. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes. Lozier JN; Thompson AR; Hu PC; Read M; Brinkhous KM; High KA; Curiel DT Hum Gene Ther; 1994 Mar; 5(3):313-22. PubMed ID: 8018746 [TBL] [Abstract][Full Text] [Related]
3. Effect of transfection time on the survival of epigastric skin flaps pretreated with adenovirus encoding the VEGF gene. Gurunluoglu R; Ozer K; Skugor B; Lubiatowski P; Carnevale K; Siemionow M Ann Plast Surg; 2002 Aug; 49(2):161-9. PubMed ID: 12187344 [TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hurwitz DR; Kirchgesser M; Merrill W; Galanopoulos T; McGrath CA; Emami S; Hansen M; Cherington V; Appel JM; Bizinkauskas CB; Brackmann HH; Levine PH; Greenberger JS Hum Gene Ther; 1997 Jan; 8(2):137-56. PubMed ID: 9017418 [TBL] [Abstract][Full Text] [Related]
6. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice. Kim HS; Kim JC; Lee YK; Kim JS; Park YS J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610 [TBL] [Abstract][Full Text] [Related]
7. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802 [TBL] [Abstract][Full Text] [Related]
8. Lentiviral transduction of face and limb flaps: implications for immunomodulation of vascularized composite allografts. Leto Barone AA; Zhou ZY; Hughes MW; Park R; Schulman RM; Lee S; Vidar EN; Shiba TL; Weber EL; Cetrulo CL Plast Reconstr Surg; 2012 Feb; 129(2):391-400. PubMed ID: 22286422 [TBL] [Abstract][Full Text] [Related]
10. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Hagstrom JN; Couto LB; Scallan C; Burton M; McCleland ML; Fields PA; Arruda VR; Herzog RW; High KA Blood; 2000 Apr; 95(8):2536-42. PubMed ID: 10753832 [TBL] [Abstract][Full Text] [Related]
11. Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. Gordon EM; Skotzko M; Kundu RK; Han B; Andrades J; Nimni M; Anderson WF; Hall FL Hum Gene Ther; 1997 Jul; 8(11):1385-94. PubMed ID: 9295133 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068 [TBL] [Abstract][Full Text] [Related]
13. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells. Dodd M; Marquez-Curtis L; Janowska-Wieczorek A; Hortelano G J Gene Med; 2014; 16(5-6):131-42. PubMed ID: 24947827 [TBL] [Abstract][Full Text] [Related]
14. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938 [TBL] [Abstract][Full Text] [Related]
15. Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids. Sam MR; Azadbakhsh AS; Farokhi F; Rezazadeh K; Sam S; Zomorodipour A; Haddad-Mashadrizeh A; Delirezh N; Mokarizadeh A Biologicals; 2016 May; 44(3):170-7. PubMed ID: 26928674 [TBL] [Abstract][Full Text] [Related]
16. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Chen ZY; He CY; Kay MA Hum Gene Ther; 2005 Jan; 16(1):126-31. PubMed ID: 15703495 [TBL] [Abstract][Full Text] [Related]
17. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX. Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911 [TBL] [Abstract][Full Text] [Related]
18. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Herzog RW; Hagstrom JN; Kung SH; Tai SJ; Wilson JM; Fisher KJ; High KA Proc Natl Acad Sci U S A; 1997 May; 94(11):5804-9. PubMed ID: 9159155 [TBL] [Abstract][Full Text] [Related]
19. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Chen ZY; He CY; Ehrhardt A; Kay MA Mol Ther; 2003 Sep; 8(3):495-500. PubMed ID: 12946323 [TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated transforming growth factor-beta ameliorates ischemic necrosis of epigastric skin flaps in a rat model. Huemer GM; Shafighi M; Meirer R; Debagge P; Piza-Katzer H; Gurunluoglu R J Surg Res; 2004 Sep; 121(1):101-7. PubMed ID: 15313382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]